innocrin
precision therapeutics

INNOCRIN PHARMACEUTICALS AND THE PROSTATE CANCER FOUNDATION (PCF) JOIN FORCES FOR INNOVATIVE PHASE 2 CLINICAL STUDY

UNIQUE DUAL CYP17 LYASE INHIBITOR AND ANDROGEN RECEPTOR ANTAGONIST (VT-464) TO BE EVALUATED IN CASTRATION-RESISTANT PROSTATE CANCER (CRPC) PATIENTS

PCF TO PROVIDE $1 MILLION FOR BIOMARKER BASED STUDY

November 13, 2014, Research Triangle Park, North Carolina – Innocrin Pharmaceuticals, Inc. (www.innocrinpharma.com), a privately held pharmaceutical company that focuses on the discovery and development of best-in-class, small molecule CYP17 lyase inhibitors announces its participation in a multi-center Phase 2 clinical study of VT-464 in prostate cancer patients resistant to next-generation androgen receptor (AR) signaling inhibitors Zytiga® or Xtandi®. Howard Scher, MD, Chief of Genitourinary Oncology Service at Memorial Sloan Kettering Cancer Center (MSKCC), is leading the study, slated to begin in early 2015. He is the recipient of a $1 million PCF Challenge Award, which will fund a significant portion of this study.

READ MORE ABOUT DR. SCHER'S CHALLENGE AWARD

"I am extremely pleased that Dr. Scher and his colleagues proposed to investigate VT-464 as the potential next-generation AR-signaling therapy," said William Moore, Ph.D., President and CEO of Innocrin. "The cutting-edge biomarker analyses incorporated into the study will help us understand why certain patients respond to VT-464 but not to Xtandi® or Zytiga® so the drug can be given to those patients who are most likely to benefit. PCF has recognized the merit of this novel approach, providing generous and critical funding support."

"There is urgent medical need for new therapies that effectively treat castration-resistant prostate cancer (CRPC) and for predictive diagnostics that identify those patients who will or will not benefit," says Dr. Scher. "The precision medicine approach will become a reality. The lyase-selective inhibitor, VT-464, and the diagnostic approaches utilized in this study are exciting examples of the progress being made."

innocrin
precision therapeutics

"Effective management of CRPC is a major milestone in prostate cancer research," commented Howard R. Soule, PhD, Chief Science Officer, Prostate Cancer Foundation. "We are especially encouraged by Dr. Scher's talent and proposed work which will help realize this elusive goal."

Co-investigators on the study include Elahe Mostaghel, MD, PhD (Fred Hutchinson Cancer Research Center), Mary-Ellen Taplin, MD and Rana McKay, MD (Dana-Farber Cancer Institute), Richard Bambury, MD (MSKCC), and Robert Montgomery, MD (University of Washington School of Medicine).

About Innocrin Pharmaceuticals, Inc. (www.innocrinpharma.com)

Innocrin discovers and develops novel, best-in-class oral inhibitors of CYP17 lyase, a validated enzyme target for the treatment of castration-resistant prostate cancer (CRPC). VT-464 and structurally-related classes of CYP17 inhibitors are wholly owned by Innocrin. CYP17 lyase inhibitors may also have high commercial potential for the treatment of breast cancer as well as non-oncologic syndromes that are due to hormonal excess including endometriosis, polycystic ovary syndrome and congenital adrenal hyperplasia. Innocrin's investors include Novartis Venture Fund, Lilly Ventures, Hatteras Venture Partners, Intersouth Partners, Lurie Holdings, and Astellas Venture Management.

About the Prostate Cancer Foundation

The Prostate Cancer Foundation (PCF) is the world's leading philanthropic organization funding and accelerating prostate cancer research. Founded in 1993, PCF has raised over $595 million and provided funding to more than 2,000 research programs at nearly 200 cancer centers and universities in 18 countries and territories. PCF advocates for greater awareness of prostate cancer and more efficient investment of governmental research funds for transformational cancer research. Its efforts have helped produce a 20-fold increase in government funding for prostate cancer. More information about PCF can be found at www.pcf.org.

Contact:
Innocrin Pharmaceuticals, Inc.
William R. Moore, President & CEO
4505 Emperor Boulevard, Suite 300
Durham, North Carolina 27703 USA
Phone 919.467.8539 x 308

wmoore@innocrinpharma.com